The perils of Alzheimer's drug development

Current Alzheimer Research

Volumn 6, Issue 1, 2009, Pages 77-78

  Schneider, Lon S ^a   Lahiri, Debomoy K ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAPINEUZUMAB; DONEPEZIL; METRIFONATE; PHENSERINE; PLACEBO; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUSTRY; GENETIC ANALYSIS; HUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; TREATMENT DURATION;

ALZHEIMER DISEASE; ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INDUSTRY; HUMANS; OBSERVER VARIATION; PHYSOSTIGMINE; SELECTION BIAS;

EID: 62149097584     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787313871     Document Type: Note

References (9)

1. Becker RE and Greig NH. Alzheimer's Disease Drug Development in 2008 and beyond: Problems and Opportunities. Curr Alzheimer Res 5(4): 346-57 (2008).
2. Schneider LS. Prevention therapeutics of dementia. Alzheimer Demen 4(1): S122-S130 (2008).
3. López-Arrieta JM and Schneider L. Metrifonate for Alzheimer's disease. Cochrane Database Syst Rev 2: CD003155 (2006).
4. Schneider LS. Issues in design and conductance of clinical trials for cognitive-enhancing drugs. In: McArthur RA and Borsini F, Eds. Animal and Translational Models of Behavioural Disorders, Neurological Disorders. Elsevier, New York 2 (2008) (in press).
5. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63(5): 621-31 (2008).
6. Altstiel LD. Barriers to Alzheimer's disease drug discovery and development in the biotechnology industry. Alzheimer Dis Assoc Disord (Supp 1): S29-S32 (2002).
7. Poirier J, Delisle M, Quirion R, Aubert I, Farlow M, Lahiri DK, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 92: 12260-12264 (1995).
8. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L and Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50(3): 669-77 (1998).
9. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6(4): 246-54 (2006).